Gene editing has spent the last decade proving what's possible in the lab. The next decade is about proving it can reach the patients who need it most, from ultra-rare liver diseases to conditions like ALS, where no truly effective treatments exist today.
Arbor Biotechnologies is one of the companies pushing that frontier, built on a diverse toolbox of editing technologies that goes beyond the limitations of first-generation CRISPR tools. Its lead clinical program, ABO-101, targets PH1, and last October the company struck a partnership with Chiesi Group worth up to two billion dollars in milestones, with European regulators granting the program orphan drug designation just this summer.
Arbor is also building out a CNS pipeline focused initially on ALS. Here to talk through the science, the strategy, and what's next is Devyn Smith, CEO of Arbor Biotechnologies.
01:36 – Meet Devyn Smith
07:48 – Arbor's toolbox approach versus single-editor CRISPR companies
12:16 – What PH1 is and how ABO-101 works
15:19 – Inside the Chiesi partnership for ABO-101
20:14 – Why ALS anchors Arbor's CNS pipeline
26:48 – Arbor's three-year outlook and long-term vision
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
To dive deeper into the topic: